P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement.
about
Bioavailability enhancers of herbal origin: an overviewA review on the strategies for oral delivery of proteins and peptides and their clinical perspectivesNanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetesBypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia TherapyPolymers influencing transportability profile of drugDioscin strengthens the efficiency of adriamycin in MCF-7 and MCF-7/ADR cells through autophagy induction: More than just down-regulation of MDR1.P-glycoprotein mediated drug interactions in animals and humans with cancerGenetic knockdown and pharmacological inhibition of parasite multidrug resistance transporters disrupts egg production in Schistosoma mansoniPrediction of promiscuous p-glycoprotein inhibition using a novel machine learning schemeInhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to PraziquantelPreactivated thiomers: their role in drug deliveryMultilayer spheroids to quantify drug uptake and diffusion in 3D.A novel method using confocal laser scanning microscopy for sensitive measurement of P-glycoprotein-mediated transport activity in Caco-2 cells.The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression.P-glycoprotein-dependent trafficking of nanoparticle-drug conjugatesP-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions.In silico quantitative structure-activity relationship studies on P-gp modulators of tetrahydroisoquinoline-ethyl-phenylamine series.Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers.HZ08 reverse P-glycoprotein mediated multidrug resistance in vitro and in vivo.Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.(1)H nuclear magnetic resonance-based extracellular metabolomic analysis of multidrug resistant Tca8113 oral squamous carcinoma cells.In silico Analysis for Predicting Fatty Acids of Black Cumin Oil as Inhibitors of P-GlycoproteinFunctional characterization of peptide transporters in MDCKII-MDR1 cell line as a model for oral absorption studiesKuguacin J isolated from Momordica charantia leaves inhibits P-glycoprotein (ABCB1)-mediated multidrug resistance.A Novel Submicron Emulsion System Loaded with Doxorubicin Overcome Multi-Drug Resistance in MCF-7/ADR CellsThiomer-coated liposomes harbor permeation enhancing and efflux pump inhibitory properties.Approaches for enhancing oral bioavailability of peptides and proteinsNatural and synthetic polymers as inhibitors of drug efflux pumps.Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety.Marine natural products with P-glycoprotein inhibitor properties.Strategies for enhanced drug delivery to the central nervous system.Geniposide reverses multidrug resistance in vitro and in vivo by inhibiting the efflux function and expression of P-glycoprotein.Berberine: a potential phytochemical with multispectrum therapeutic activities.Herb-drug pharmacokinetic interactions reviewed.The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review.Diverse approaches for the enhancement of oral drug bioavailability.Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer.Targeting receptors, transporters and site of absorption to improve oral drug delivery.Excipients with specialized functions for effective drug delivery.Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
P2860
Q24631494-0562E694-F358-466F-9AEE-63981BC20E69Q26744008-EA76ED41-268A-4386-AEED-D981E7144922Q26779447-4ED9FC9A-EEC7-4874-8D3D-E6DA744CF04AQ26780502-9793C271-3050-4C1F-97FE-C12FCE4BF67DQ26862824-59711EE0-2E30-4F69-B4A3-0017890D4720Q27335381-EA3497D5-4A65-4957-B0A5-0332B47FE8FCQ28085291-8C3A48F0-17AE-475C-BAE7-70F3ECBAFD4EQ28478288-28EABB1C-FB6D-403C-B6CC-CB18F1F4A2F7Q28481547-0115E637-9183-4465-88EC-D66B5EA8AAD2Q28543846-EDCE1746-9335-4BFE-B1EB-D747E338A927Q29543207-16366436-2E8C-4B2D-84C5-5D35F28687E0Q33894623-93C7AF6A-C444-4F9F-B967-B32FE1434BF5Q33947052-5B8F6E9E-848F-41F6-9AAB-4BD63FFC95E9Q33961526-CA69B6C1-53AE-46BD-AD06-B96CE10BA607Q34062299-1B6B70FE-0E90-473A-94C1-59FEAB158982Q34171741-695C977F-001C-45D5-AE8A-BB28105052ABQ34570476-83E510BD-BCDA-4243-B93E-AC011E8ADF07Q34571054-7297807B-7830-40E2-8C93-3CABD03AC765Q35091852-58221B00-80DF-4B22-B920-4AA8472CE5B7Q35196290-5E7B6158-DCF6-45ED-9A4F-2DA56DEAF5A5Q35758072-83E46A7E-E122-444F-86F4-F5EE569B77E9Q35970006-CA35FC96-DF94-4240-8180-4C0C32BE718FQ36004628-AE45EDB2-375F-401E-AB6D-97DAB9CBF112Q36088702-795A74E2-3139-4081-A8AE-F256F79DA34CQ36291842-0D95DBFA-09A3-49BD-8071-248BCE9BA8D5Q36575250-6B2E2B05-D0F3-4D6D-942A-DF409970F3A5Q36922557-B6790F4C-F11C-45D4-8D25-05E5E5A87E5DQ36951710-0D450389-7843-4048-B106-668517962434Q36960535-B14F7DB8-4D5D-4E51-8951-BC97B3655514Q37566253-9C51FB17-8C83-49D6-AA63-922223C5A694Q37666694-9ED77170-AEE1-4E32-AF67-58FFAC833279Q37697601-0818FF1E-CB8B-4BEA-87D9-6E3D4603A849Q37788220-D06F0D5D-7B3B-4606-A154-058FCB25A1BBQ37808478-CF1EE205-B09E-4161-BA09-3F8D64428436Q37854074-84E38D2A-B08B-4356-8A1C-E157C7BE0F5AQ37863645-AB088929-FCBE-4FFA-9B3B-2373B5A4A3FFQ37869444-0BC846DE-A7FE-491A-A973-AD580D96C768Q37928909-373FDB30-ECD4-4FFF-BD0D-F62A4150A33CQ37971124-519EFDD1-B26A-46B6-8D03-5A7DD1CAAB9BQ38003174-A4C22F90-B6C6-4DF0-A018-981D93DD8C24
P2860
P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
P-glycoprotein inhibitors and ...... m bioavailability enhancement.
@ast
P-glycoprotein inhibitors and ...... m bioavailability enhancement.
@en
type
label
P-glycoprotein inhibitors and ...... m bioavailability enhancement.
@ast
P-glycoprotein inhibitors and ...... m bioavailability enhancement.
@en
prefLabel
P-glycoprotein inhibitors and ...... m bioavailability enhancement.
@ast
P-glycoprotein inhibitors and ...... m bioavailability enhancement.
@en
P2093
P1476
P-glycoprotein inhibitors and ...... m bioavailability enhancement.
@en
P2093
Chinmoy S Dey
Manthena V S Varma
Ramesh Panchagnula
Yasvanth Ashokraj
P304
P356
10.1016/S1043-6618(03)00158-0
P577
2003-10-01T00:00:00Z